To determine the functional relevance of MAPK pathway activation mediated by PLA2G16 expression in osteosarcoma progression, we used U0126 monoethanolate (a MEK specific inhibitor) to inhibit the phosphorylation of ERK1/2 (Figure 7A) and examined the clonogenic survival and migration abilities in Saos2 and MG63 cells. This evidence concerns the gene MAPK3 and osteosarcoma.